Inovio Pharmaceuticals, Inc. (INO)
After hours:
- PR Newswire
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million. This investment adds Shanghai Healthcare Capital (SHC) to Geneos' investor syndicate. Dr. Jing Bao will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.
- PR Newswire
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP). The FDA's Breakthrough Therapy designation is a process designed to expedite the development and
- PR Newswire
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference.
